Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Boswellia serrata extract is a standardized or crude preparation obtained from the resin of the Indian frankincense tree (Boswellia serrata), well known in Ayurvedic medicine. Its most studied constituents are boswellic acids (e.g., 3-acetyl-11-keto-β-boswellic acid, β-boswellic acid), which play key roles as anti-inflammatory agents by inhibiting leukotriene synthesis and modulating various immune pathways. Commercial preparations such as Boswellin Super (BSE) may be standardized to a specific percentage of boswellic acids. Boswellia extract is not a specific molecular target and can vary widely in composition, making precise molecular classification impossible; thus, it should not be cited as a drug target or receptor. It is most accurately referred to as a bioactive botanical mixture with anti-inflammatory and immunomodulatory properties, but not as a molecular target for pharmaceuticals.
Inhibition of 5-lipoxygenase (5-LOX), reducing leukotriene biosynthesis; Modulation of cyclooxygenase (COX) pathways; Modulation of immune cell activation and cytokine production; Induction of apoptosis in tumor cells (select boswellic acid derivatives).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Boswellia serrata extract.